These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10710174)

  • 1. The use of the Panic and Agoraphobia Scale in a clinical trial.
    Bandelow B; Brunner E; Broocks A; Beinroth D; Hajak G; Pralle L; Rüther E
    Psychiatry Res; 1998 Jan; 77(1):43-9. PubMed ID: 10710174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a new statistical approach to evaluate a clinical trial with panic disorder patients.
    Bandelow B; Brunner E; Beinroth D; Pralle L; Broocks A; Hajak G; Rüther E
    Eur Arch Psychiatry Clin Neurosci; 1999; 249(1):21-7. PubMed ID: 10195340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM; Talbott-Green M; Sloan C
    Biol Psychiatry; 1998 Jun; 43(11):848-54. PubMed ID: 9611676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
    Marchesi C; Ampollini P; Signifredi R; Maggini C
    Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale.
    Furukawa TA; Katherine Shear M; Barlow DH; Gorman JM; Woods SW; Money R; Etschel E; Engel RR; Leucht S
    Depress Anxiety; 2009; 26(10):922-9. PubMed ID: 19006198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems.
    Bandelow B; Hajak G; Holzrichter S; Kunert HJ; Rüther E
    Int Clin Psychopharmacol; 1995 Jun; 10(2):83-93. PubMed ID: 7673660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the severity of panic disorder and agoraphobia: validity, reliability and objectivity of the Turkish translation of the Panic and Agoraphobia Scale (P&A).
    Tural U; Fidane H; Alkin T; Bandelow B
    J Anxiety Disord; 2002; 16(3):331-40. PubMed ID: 12214818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
    Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N
    Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DSM-II personality characteristics of panic disorder with agoraphobia patients in stable remission.
    Mavissakalian M; Hamann MS
    Compr Psychiatry; 1992; 33(5):305-9. PubMed ID: 1356708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale.
    Bandelow B
    Int Clin Psychopharmacol; 1995 Jun; 10(2):73-81. PubMed ID: 7673659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial.
    Bandelow B; Broocks A; Pekrun G; George A; Meyer T; Pralle L; Bartmann U; Hillmer-Vogel U; Rüther E
    Pharmacopsychiatry; 2000 Sep; 33(5):174-81. PubMed ID: 11071019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
    Mezzasalma MA; Mathias Kde V; Nascimento I; Valença AM; Nardi AE
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):196-201. PubMed ID: 21537560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panic Disorder Severity Scale: reliability and validity of the Turkish version.
    Monkul ES; Tural U; Onur E; Fidaner H; Alkin T; Shear MK
    Depress Anxiety; 2004; 20(1):8-16. PubMed ID: 15368591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panic disorder subtypes: further clinical differences.
    Onur E; Alkin T; Tural U
    Depress Anxiety; 2007; 24(7):479-86. PubMed ID: 17106872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
    Scheibe G; Albus M
    J Affect Disord; 1996 Nov; 41(2):111-6. PubMed ID: 8961038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure of phobias in panic disorder.
    Argyle N; Solyom C; Solyom L
    Br J Psychiatry; 1991 Sep; 159():378-82. PubMed ID: 1958949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
    Mavissakalian MR; Perel JM
    J Clin Psychopharmacol; 2002 Jun; 22(3):294-9. PubMed ID: 12006900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
    Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
    J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 15-year follow-up study of patients with panic disorder.
    Andersch S; Hetta J
    Eur Psychiatry; 2003 Dec; 18(8):401-8. PubMed ID: 14680716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.